Who is sponsoring NCT02813785?

NCT02813785 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT02813785?

Interventions in NCT02813785: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel.

What condition does NCT02813785 study?

NCT02813785 studies Carcinoma, Non-Small-Cell Lung.

Is NCT02813785 still recruiting?

NCT02813785 is currently completed. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT02813785: IMpower210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed Phase 3 Last updated 10 January 2023

What this trial tests

Phase 3 trial testing Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody in Carcinoma, Non-Small-Cell Lung in 565 participants. Completed in 27 December 2022.

Timeline

1 July 2016

Primary endpoint
1 August 2019

27 December 2022

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	565
Start date	1 July 2016
Primary completion	1 August 2019
Estimated completion	27 December 2022
Sites	38 locations across Malaysia, South Korea, Thailand, China, Singapore

Drugs / interventions tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase III, multicenter, open-label, randomized, controlled study is designed to evaluate the efficacy and safety of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab compared with docetaxel in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression, loss of clinical benefit, or unacceptable toxicity.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors: recent progress and potential biomarkers.
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. · · 2018 · cited 1495× · PMID 30546008 · DOI 10.1038/s12276-018-0191-1
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX, Huang JM, Jiang ZB, Li RZ, et al · · 2019 · cited 45× · PMID 31838881 · DOI 10.1177/1534735419890020
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Liu SY, Wu YL. · · 2017 · cited 38× · PMID 28679395 · DOI 10.1186/s13045-017-0506-z
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Seetharamu N, Preeshagul IR, Sullivan KM. · · 2017 · cited 28× · PMID 28761384 · DOI 10.2147/lctt.s113177
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Facchinetti F, Bordi P, Leonetti A, Buti S, et al · · 2018 · cited 9× · PMID 30237696 · DOI 10.2147/dddt.s124380
IMpower210: A phase III study of second-line atezolizumab <i>vs.</i> docetaxel in East Asian patients with non-small cell lung cancer.
Wu YL, Lu S, Chen G, He J, et al · · 2024 · cited 5× · PMID 38751442 · DOI 10.21147/j.issn.1000-9604.2024.02.01
Standard of care in immunotherapy trials: Challenges and considerations.
Rivalland G, Scott AM, John T. · · 2017 · cited 3× · PMID 28267397 · DOI 10.1080/21645515.2016.1277845

Verify or expand the search:

Other trials of Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

Trials testing the same drug.

NCT03456063 — A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage · Phase 3 · completed
NCT03191786 — A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced · Phase 3 · completed
NCT02927301 — A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Canc · Phase 2 · completed
NCT02763579 — A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) S · Phase 3 · completed
NCT02431208 — A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulato · Phase 1 · completed

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02813785 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02813785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing